InvestorsHub Logo
Followers 32
Posts 3238
Boards Moderated 0
Alias Born 08/31/2006

Re: None

Tuesday, 08/08/2017 5:13:00 PM

Tuesday, August 08, 2017 5:13:00 PM

Post# of 15799
OPKO Q2 top line off 12%; earnings down 213%; shares off 2% after hours

Aug. 8, 2017 4:56 PM ET|About: OPKO Health, Inc. (OPK)|By: Douglas W. House, SA News Editor

OPKO Health (NYSEMKT:OPK) Q2 results ($M): Total Revenues: 314.2 (-12.0%), includes $10M milestone from TESARO triggered by commercial launch of VARUBY in Europe.

Net Loss: (17.5) (-212.9%); Loss/Share: (0.04) (-300.0%).

Salesforce expansion doubled to 70 to support RAYALDEE.

Five Phase 2 studies to be initiated through Q1 2018: RAYALDEE in dialysis patients with SHPT, OPK88004 in BPH, OPK88003 in T2D and obesity, OPK88002 in pruritis and OPK88001 in Dravet syndrome.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News